GB2165151A - Pharmaceutical compositions for acne treatment - Google Patents
Pharmaceutical compositions for acne treatment Download PDFInfo
- Publication number
- GB2165151A GB2165151A GB08524054A GB8524054A GB2165151A GB 2165151 A GB2165151 A GB 2165151A GB 08524054 A GB08524054 A GB 08524054A GB 8524054 A GB8524054 A GB 8524054A GB 2165151 A GB2165151 A GB 2165151A
- Authority
- GB
- United Kingdom
- Prior art keywords
- composition
- cysteine
- propylene
- phenoxetol
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 15
- 206010000496 acne Diseases 0.000 title claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 67
- 239000004201 L-cysteine Substances 0.000 claims abstract description 31
- 235000013878 L-cysteine Nutrition 0.000 claims abstract description 31
- IBLKWZIFZMJLFL-UHFFFAOYSA-N 1-phenoxypropan-2-ol Chemical compound CC(O)COC1=CC=CC=C1 IBLKWZIFZMJLFL-UHFFFAOYSA-N 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 40
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- 239000003349 gelling agent Substances 0.000 claims description 9
- 229920002125 Sokalan® Polymers 0.000 claims description 7
- 239000003906 humectant Substances 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 239000004584 polyacrylic acid Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 abstract description 2
- 229960002433 cysteine Drugs 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000000499 gel Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- 239000004408 titanium dioxide Substances 0.000 description 4
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229920003319 Araldite® Polymers 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 2
- 229930195710 D‐cysteine Natural products 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical class [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010052891 Skin bacterial infection Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- -1 alkylene glycols Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002910 effect on acne Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000001455 metallic ions Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Pharmaceutical compositions useful in the treatment of acne comprising L-cysteine or a pharmaceutically acceptable salt thereof and an antibacterial agent such as propylene phenoxetol together with a pharmaceutically acceptable carrier.
Description
SPECIFICATION
Pharmaceutical compositions
The present invention relates to pharmaceutical compositions useful in the treatment of acne which compositions comprise L-cysteine or a pharmaceutically acceptable salt thereof and propylene phenoxetol.
Anti-acne treatments are well known but none are sufficiently satisfactory as to obviate the need of a further method of treatment. Known methods of treatment by ultra-violet radiation, x-rays or surgery can cause tissue to be destroyed or the sebaceous glands to atrophy; conventional oestrogen therapy similarly atrophies the sebaceous glands and may additionally be unacceptable to female patients and may require a considerable time to have an effect; and treatment with benzoyl peroxide can cause local irritation. Clearly it would be desirable to offer an alternative method of treating acne.
The present invention is based upon the discovery that compositions containing L-cysteine and propylene phenoxetol may be used to treat acne without an unacceptable level of undesirable side effects such as the destruction of tissues to an unacceptable degree.
Accordingly, the present invention provides a pharmaceutical composition useful in the treatment of acne which composition comprises L-cysteine or a pharmaceutically acceptable salt thereof and propylene phenoxetol.
One of the considerable advantages of using cysteine in the treatment of acne is that the medical practitioner will be aware that it is a natural amino acid, so that confidence may be felt in that unconventional and possibly irritant materials such as thioglycolic acid can be avoided (U.S. Patent No. 4107330 discloses the topical applications of thioglycolic acid in the treatment of acne). Organic sulfhydryl and in particular N-acetyl cysteine have been applied to the skin in order to reduce sebum production (see U.K.
Patent No. 1317773) but they were not shown to have any effect on acne. L-cysteine has been used in the treatment of eye diseases (see German Published Patent Application No. 2441621) but that use is unrelated to the treatment of acne.
Propylene phenoxetol, 1-phenoxypropan-2-ol, has been used in topical compositions for the trea...1ent of skin bacterial infections and skin fungal infections. Its use, together with L-cysteine in the treatment of acne has not been disclosed or suggested.
The usefulness of L-cysteine and propylene phenoxetol in the treatment of acne is therefore particularly surprising.
The L-cysteine and propylene phenoxetol are normally applied in the form of a pharmaceutical composition which comprises L-cysteine or a pharmaceutically acceptable salt thereof and propylene phenoxetol and a pharmaceutically acceptable carrier therefor. The L-cysteine may have D-cysteine in association therewith if desired but normally and preferably L-cysteine is employed free of D-cysteine. Any convenient composition may be employed as long as it is free of oxidising agents or other agents incompatible with L-cysteine oropropylene phenoxetol. Compositions analogous to those of the aforementioned patent documents may be employed if desired. However it is preferred to employ a self-supporting aqueous gel.
Accordingly this invention provides a pharmaceutical composition adapted for topical administration in the form of a self-supporting aqueous gel containing L-cysteine or a pharmaceutically acceptable salt thereof and propylene phenoxetol.
Acceptable salts of cysteine include those with topically acceptable metallic ions or nitrogenous bases or topically acceptable acids. A particularly apt salt is the hydrochloride. By a self-supporting gel is meant a gel which when applied to an area of skin remains in contact with the area.
Most suitably the composition of this invention will contain from 0.1 to 15% of L-cysteine or a pharmaceutically acceptable salt thereof, more favourably 2.0 to 12% and preferably from 4 to 8% (% terms when used herein are expressed on a wt./wt. basis).
Most suitably the composition of this invention will contain from 0.1 to 5% of propylene phenoxetol, 1phenoxypropan-2-ol, more favourably 1 to 4%, and preferably from 1.5 to 3%, for example 2%.
Optionally, though not preferred, the composition of this invention will contain preservative. Preservatives which are most apt are those commonly used in pharmaceutical compositions. Preferably the preservative will be benzoic acid, in an amount of 0.01 to 0.5% preferably 0.05 to 0.2%.
Normally and preferably the composition will contain a pharmaceutically acceptable gelling agent such as cellulose derivatives or gums or starches or alginates and polymers such as polyvinyl pyrrolidone or polyvinyl alcohol or polyethoxy-polypropoxy glycol copolymers, but a preferred gelling agent is a polyacrylic acid lightly cross-linked with triallyl sucrose. Such polymers are known as carboxyvinyl polymers of which the Carbopols (Trade Mark) are one commerciai embodiment. To form gels these polymers must be neutralised. Suitable neutralising agents include solutions of alkali metal or ammonium hydroxides and nitrogenous bases. A preferred neutraliser is a solution of sodium hydroxide.
Suitably the pharmaceutical compositions of the present invention in the form of a gel will contain from 0.1 to 5% of gelling agent depending on the efficacy of the agent, more suitably 0.5 to 4% and preferably 1 to 3%, for example 1.5%, 2% or 2.5%.
Normally and preferably the composition will contain a humectant to prevent the gel drying in use.
Such humectants include alkylene glycols. A particularly preferred humectant is propylene glycol. This agent has the added advantage in easing the dispersion of the gelling agent in the bulk of the water during preparation. Suitably the composition may contain from 2 to 10% of humectant and preferably 3 to 7%.
Most suitably the pH of the composition will be controlled to prevent oxidation of L-cysteine base to cystine which occurs readily in solutions having a PH value of greater than 8. The suitable range of pH value is from 2 to 8, most suitably from 3 to 6 and preferably 4 to 6.
The pH value of a gel composition may also depend upon the choice of gelling agent and the viscosity required for the final gel. Thus, if the pH value is at the higher end of the range a hydroxyethyl cellulose gelling agent may be used and for gels of lower pH the preferred gelling agent is a polyacrylic acid lightly cross-linked by triallyl sucrose, when for example pH values of 4.5 and 5.5 are employed.
The viscosity of the final gel were measured using a Ferranti-Shirley cone and plate viscometer using the following parameters.
4 cm cone
120 second sweep time
600g cm ' torquf spring
10 rpm speed 25 C temperature
The apparent viscosity at maximum sheer (10 r.p.m. = 113.7 sec-1) is suitably between 30 and 80 poise and is preferably between 60 and 75 poise.
Optionally the compositions of the present invention may also contain other ingredients including perfumes and inert fillers such as titanium dioxide to provide a white rather than colourless gel.
Normally and preferably the water used in the composition will be freshly distilled water which has been de-oxygenated by boiling and allowed to cool with filtered 'inert' gas bubbling through it. By 'inert' gas is meant a non-oxidising gas for cysteine, for example carbon dioxide, particularly preferred as nitrogen. It is also envisaged that any type of water for example deonized water, may be used provided it is degassed to remove oxygen and maintained thereafter under nitrogen. L-cysteine and its salts are readily oxidised in aqueous solutions by oxygen dissolved in the water, hence removal of this oxygen and isolation of this solution from air, avoids oxidation of L-cysteine and its salts.
The particularly favoured form of the composition of the present invention comprises from 2 to 12% of
L-cysteine hydrochloride, 1 to 4% of propylene phenoxetol, 2 to 10% propylene glycol, 0.1 to 5% polyacrylic acid cross-linked by triallyl sucrose, sodium hydroxide solution to give a pH of 5.4 and sufficient water to adjust the volume to 100%.
A preferred form of the composition of the present invention comprises from 4 to 8% of L-cysteine, 1.5 to3% propylene phenoxetol, 5% propylene glycol, 1.5% polyacrylic acid lightly cross-linked with triallyl sucrose, sodium hydroxide solution to adjust the pH of 5.4 and sufficient water to adjust the volume to 100%.
Typically the composition of the present invention will be packed into araldite laquered aluminium tubes.
In a second aspect therefore the invention provides a method of treating acne which comprises applying topically te the affected areas an effective amount of L-cysteine or a pharmaceutically acceptable salt thereof and propylene phenoxetol. The composition will be applied topically to the affected area 2 times daily or more frequently if required.
In severe cases it may be desirable to apply the composition to the affected area up to 6 times a day for example, 2, 3, 4, 5 or 6 times daily. Generally 2, 3 or 4 applications daily are most convenient and usually 2 or 3 applications will be made. In mild cases a single application per day may be envisaged.
Generally, treatment will last for at least 7 days and may proceed for up to 14 to 28 days or even longer if a physician considers it desirable.
In view of the susceptibility of cysteine to oxidation, the skilled worker will be aware that the compositions employed will be free of agents that would oxidise the cysteine.
Although propylene phenoxetol is the preferred anti-bacterial agent in a less favoured aspect alternative anti-bacterial agents may be employed. Thus in a broader aspect the present invention provides a pharmaceutical composition useful in the treatment of acne which composition comprises L-cysteine or a pharmaceutically acceptable salt thereof and an anti-bacterial agent.
Aptly the composition will contain from 0.1 to 15% of L-cysteine or a pharmaceutically acceptable salt thereof. Suitably the composition will contain from 0.2 to 2.0% L-cysteine or a pharmaceutically acceptable salt thereof, more suitably will contain 0.25 to 1.5% and preferably 0.3 to 0.5%, for example 0.35%, 0.40% and 0.45% of L-cysteine or a pharmaceutically aceptable salt thereof. Preferably the hydrochloride of L-cysteine is employed.
The effectiveness of compositions containing such low concentrations of L-cysteine with the antibacterial agent is particularly surprising. Such concentrations have the added advantage of being particularly friendly towards the skin.
Apt anti-bacterial agents are those which are compatible with L-cysteine. Suitable anti-bacterial agents include quaternary ammonium salts, for example benzalkonium chloride and propylene phenoxetol. The preferred anti-bacterial agent is propylene phenoxetol.
The following Examples are illustrative of the invention.
Example 1
An aqueous gel was made containing:
L-cysteine 7.0% w/w 2109 Propylene phenoxetol 2.5% w/w 759 Propylene glycol 4.5% w/w 1359
Carbopol 934P 2.0% w/w 609 Sodium hydroxide solution to adjust the pH to 5.4
Distilled water to adjust the volume to 100% w/w 2520g.
The freshly distilled water was boiled to remove dissolved oxygen and allowed to cool with filtered nitrogen bubbling through. Nitrogen was bubbled through the bulk of the composition for the entirety of the process including the filling. The Carbopol 934P was dissolved in the water by warming and stirring.
Then the water was allowed to cool to ambient temperature. The propylene phenoxetol was dispersed in the propylene glycol and then added to the cool water with stirring. The L-cysteine was then dissolved in the solution and the pH adjusted to pH 5.4 using soidum hydroxide solution. The weight of solution was adjusted to the weight required by addition of deoxygenated water. The resultant solution was mixed for a further 15 minutes under a nitrogen blanket. The resultant clear product was transferred to a tube filling apparatus under a blanket of nitrogen. The product was filled in a conventional manner into araldite lacquered aluminium tubes which have been flushed with nitrogen. The tubes were sealed immediately.
The gel was dispensed from the tube as required.
Example 2
An aqueous gel was made containing:
L-cysteine 8.0%
Propylene phenoxetol 2.0%
Propylene glycol 7.0%
Carbopol 934P 1.25%
Titanium dioxide 0.25%
Perfume 0.05%
Sodium hydroxide solution to adjust pH to 5.2
Distilled water to adjust the weight to 100%.
The gel was formed and packed using the methods described in Example 1. The titanium dioxide and perfume were added along with the propylene phenoxetol after first mixing with the propylene glycol.
Example 3
An aqueous gel was made containing:
L-cysteine hydrochloride 10%
Propylene phenoxetol 2%
Propylene glycol 6%
Carbopol 934P 2%
Sodium hydroxide solution to adjust the pH to 4.5
Distilled water to adjust the weight to 100g.
The gel was prepared and packaged in a similar manner to that described in Example 1.
Example 4
An aqueous gel was prepared containing:
L-cysteine hydrochloride 0.45%
Propylene glycol 6.0%
Carbopol 934P 1.5%
Titanium dioxide 0.25%
Perfume 0.06%
Sodium hydroxide solution to adjust the pH to 5.6
Distilled water to adjust the weight to 1009.
The gel was formed in a similar manner to that described in Example 2.
An aqueous gel was prepared containing:
L-cysteine 0.35%
Propylene phenoxetol 2.0%
Propylene glycol 7.0%
Carbopol 934P 1.25%
Perfume 0.05%
Sodium hydroxide solution to adjust the pH to 5.2
Distilled water to adjust the weight to 1009.
The gel was formed in a similar manner to that described in Example 1.
Claims (1)
1. A pharmaceutical composition useful in the treatment of acne which composition comprises L-cysteine or a pharmaceutically acceptable salt thereof and propylene phenoxetol.
2. A composition as claimed in claim 1 which comprises from 0.1 to 15% of L-cysteine or a pharmaceutically acceptable salt thereof.
3. A composition as claimed in either of claims 1 or 2 which comprises from 0.1 to 5% of propylene phenoxetol.
4. A composition as claimed in any of claims 1 to 3 in which the composition is in the form of a selfsupporting aqueous gel.
5. A composition as claimed in claim 4 in which the composition comprises from 0.1 to 5% of gelling agent.
6. A composition as claimed in claim 5 in which the gelling agent is polyacrylic acid lightly cross linked with triallyl sucrose.
7. A composition as claimed in any of claims 4 to 6 which comprises from 2 to 10% of a humectant.
8. A composition as claimed in claim 7 in which the humectant is propylene glycol.
9. A composition as claimed in any of claims 1 to 8 in which the composition has a pH in the range 3 to 6.
10. A pharmaceutical composition useful in the treatment of acne which composition comprises Lcysteine or a pharmaceutically acceptable salt.
12. A pharmaceutical composition as claimed in either of claims 10 or 11 which contains from 0.1 to 5% of antibacterial agent.
13. A pharmaceutical composition as claimed in claim 12 in which the antibacterial agent is propylene phenoxetol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08524054A GB2165151B (en) | 1984-10-03 | 1985-09-30 | Cysteine containing compositions for treating acne |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB848424957A GB8424957D0 (en) | 1984-10-03 | 1984-10-03 | Pharmaceutical compositions |
| GB08524054A GB2165151B (en) | 1984-10-03 | 1985-09-30 | Cysteine containing compositions for treating acne |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB8524054D0 GB8524054D0 (en) | 1985-11-06 |
| GB2165151A true GB2165151A (en) | 1986-04-09 |
| GB2165151B GB2165151B (en) | 1988-08-10 |
Family
ID=26288295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB08524054A Expired GB2165151B (en) | 1984-10-03 | 1985-09-30 | Cysteine containing compositions for treating acne |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2165151B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995016431A1 (en) * | 1993-12-15 | 1995-06-22 | Kabushiki Kaisya Advance | Cosmetic |
-
1985
- 1985-09-30 GB GB08524054A patent/GB2165151B/en not_active Expired
Non-Patent Citations (1)
| Title |
|---|
| MARTINDALE, THE EXTRA PHARMACOPOCIA, 28TH EDITION (1982) PAGE 50 ENTRY 579-E (SEE }PREPARATIONS-CYSTEIRE EYE-DROPS}) * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995016431A1 (en) * | 1993-12-15 | 1995-06-22 | Kabushiki Kaisya Advance | Cosmetic |
| US5650149A (en) * | 1993-12-15 | 1997-07-22 | Kabushiki Kaisya Advance | Cosmetic composition for proliferating indigenous bacteria on skin |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2165151B (en) | 1988-08-10 |
| GB8524054D0 (en) | 1985-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4981875A (en) | Medicaments for the region of the oral cavity | |
| DE3687458T2 (en) | FILM-FORMING MEDICINAL PRODUCTS FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS ON NAILS | |
| JP5546086B2 (en) | Antibacterial hydrogel with thixotropic properties that is local and not cytotoxic | |
| JPH0212451B2 (en) | ||
| US4317814A (en) | Preparation and method for treating burns | |
| US4264581A (en) | Sunscreen composition | |
| HU204435B (en) | Process for producing stabile, cosmetically acceptable gel-compositions for topical treating acne | |
| EA004537B1 (en) | Ascorbic acid composition and method for treatment of aging or damaged skin | |
| HU216720B (en) | Cosmetic and/or dermatological composition containing hydrophylic support and vitamin c and its use | |
| US4352794A (en) | Beta-cyclodextrin as anti-acne agent | |
| HUT53518A (en) | Process for producing skin moistening pharmaceutical composition comprising vitamins a as active ingredient | |
| US5575995A (en) | Ferric subsulfate gel and methods of using same | |
| US5039515A (en) | Mouth cleansing preparation | |
| JPH03501619A (en) | Gel for optimal release of antibacterial fluoride effective in preventing root caries | |
| US4518583A (en) | Hemorrhoid and anorectal disease treatment method | |
| JP2009510087A (en) | Stable ascorbic acid composition | |
| US6123930A (en) | Composition for the treatment of the nails, containing a sulphur-bearing aminoacid | |
| US4804530A (en) | Anaerobe-selective antibacterial compositions and methods | |
| US5028414A (en) | Anaerobe-selective antibacterial compositions and methods | |
| GB2165151A (en) | Pharmaceutical compositions for acne treatment | |
| CA1266002A (en) | Acne treating composition containing l-cysteine | |
| EP0659401A1 (en) | Semi-paste oral preparations comprising povidone-iodine, potassium iodide and a sugar alcohol | |
| YU13599A (en) | Use of pharmaceutical composition for preparation of medicament in a gel form | |
| US5240945A (en) | Method and compositions for treating acne | |
| US5462728A (en) | Pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19940930 |